System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Frédéric Bérard is an expert in Allergy at Centre Hospitalier Lyon Sud (France). As of October 2026, ScienceLeadR ranks Frédéric Bérard in the top 1% of experts worldwide for Hypersensitivity. Frédéric Bérard has authored 328 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 3 of them ongoing. SLR score: 826 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Frédéric Bérard Centre Hospitalier Lyon Sud France
826 ScienceLeadR Reputation 826

Unlock

Register Login
Network Map

Allergy

Subspecialties: Immunology - Dermatology - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1996 - 2026
Source: PubMed

Centre Hospitalier Lyon Sud

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 328

Citations

Citations: 5 718 1st author: 17 Last author: 78 Unique author: 4

Main journals

Revue française d'allergologie 84
Ann Dermatol Venereol 72
Eur J Dermatol 23
Allergy 9
Br J Dermatol 8

Best Journals

Lancet 1
N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Pembrolizumab-induced immediate hypersensitivity reactions.
PMID 42264219 — hypersensitivity, drug hypersensitivity, anaphylaxis, basophil degranulation test, hypersensitivity, immediate		J Allergy Clin Immunol Pract20260
Genomic and clinical characterization of anogenital basal cell carcinoma: A retrospective and prospective cohort study.
PMID 40854498 — cells, cohort studies, vulva, dermatology, mutation, carcinoma, basal cell		J Am Acad Dermatol20250
Skin's molecular signature may help guide treatment of complex inflammatory skin diseases.
PMID 40411182 — skin, skin diseases, therapeutics		J Eur Acad Dermatol Venereol20250
Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin.
PMID 40252634 — pharmaceutical preparations, exanthema, drug-related side effects and adverse reactions, therapeutics		Eur J Cancer20250
Facteurs prédictifs d’allergie immédiate aux médicaments indiquant la réalisation des tests cutanés et leur répétition en cas de négativité
OpenAlex W4408764513		Revue française d'allergologie20250

Clinical Studies 8

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 6
N/A 1
Phase 2 1

By status:

Completed 5
Recruiting 2
Active not recruiting 1

By type:

Interventional 8

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 1
multicentricup10 4

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A 52 week multi center randomized double blind placebo controlled basket study with an open label extension to investigate the efficacy safety and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1 antihistamines
2023-505739-12-01 — histamine antagonists, safety, urticaria, multiple chronic conditions, chronic inducible urticaria		Phase 3Active not recruiting2024
A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial
2025-524078-40-00 — urticaria, multiple chronic conditions, therapeutics		Phase 3Recruiting2026
A 12 week randomized participant and investigator blinded placebo controlled exploratory study in adult participants with Chronic Urticaria to assess the efficacy and safety and explore the Mechanism of Action of remibrutinib (LOU064)
2024-516355-41-00 — chronic urticaria, safety, urticaria, chronic inducible urticaria		Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS